TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be women 18 years and older who have biopsy proven endometrial or cervical carcinoma (of any histologic subtype).~* Surgical staging with the da Vinci Si robotic tool must be planned with a planned pelvic and, in the case of endometrial cancer, a para-aortic lymphadenectomy~* Patients must meet criteria for robotic surgical approach:~* Patients must have either a clinical stage I endometrial (of any histologic grade) or FIGO stage IA2 or IB1 (\<4cm) cervical squamous, adenocarcinoma or adenosquamous carcinoma.~* Patients must be able to sign an informed consent in English language.~* Patients with known liver disease will require normal range liver function tests as determined by pre-operative labs drawn within 30 days of surgery.~Exclusion Criteria:~* Patients who have iodide allergies~* Patients who have had previous retroperitoneal surgery~* Patients on whom pelvic+/- para-aortic lymphadenectomy is not planned as part of their surgical staging.~* Patients who have received previous treatment for their endometrial or cervical cancer (particularly hysterectomy or pelvic radiation).~* Patients who are pregnant.~* Patients with documented liver disease who have abnormalities of liver function tests.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IC Green Arm (Type: EXPERIMENTAL): One arm only: Receives IC Green for testing of study objective

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria:~* Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.~Severity of disease meeting all of the following three criteria:~* PASI score of 12 or greater,~* Investigator's Global Assessment (IGA) score of 3 or greater~* Total body surface area (BSA) affected of 10% or greater.~* Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.~Exclusion criteria:~* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).~* Current drug-induced psoriasis.~* Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.~* Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.~* Hematological abnormalities.~* History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.~* History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.~* Pregnant or nursing (lactating) women.~* Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457150 mg- Induction period Only(IPO) (Type: EXPERIMENTAL): secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
- AIN457 300 mg - IPO (Type: EXPERIMENTAL): secukinumab- 2 x 150mg injections per dose
- AIN457 150 mg - Fixed Interval (FI) (Type: EXPERIMENTAL): 1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
- AIN457 300 mg FI (Type: EXPERIMENTAL): 2 s.c. secukinumab 150 mg injections
- AIN457 150 mg- Start of relapse (SoR) (Type: EXPERIMENTAL): 1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
- AIN457 300 mg- SoR (Type: EXPERIMENTAL): 2 s.c. secukinumab 150 mg injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have documented multiple myeloma and measurable disease~* Must have received at least 1 prior line of therapy for multiple myeloma and achieved a response (partial response or better) to at least one prior regimen~* Must have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimen~* Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2~* If a participant has received subsequent anticancer therapy (salvage therapy), the participant must have a wash-out period defined as 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the planned start date of daratumumab monotherapy. The only exception is the emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day for a maximum of 4 days) before Daratumumab monotherapy~Exclusion Criteria:~* Has received any of the following therapies: daratumumab or other anti-CD38 therapies~* Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment~* Disease shows evidence of refractoriness or intolerance to lenalidomide or if previously treated with a lenalidomide-containing regimen the participant is excluded if he or she discontinued due to any adverse event related to prior lenalidomide treatment~* Has received autologous stem cell transplantation within 12 weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of disease~* History of malignancy (other than multiple myeloma) within 5 years before the first dose of daratumumab monotherapy (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daratumumab + lenalidomide + dexamethasone (Type: EXPERIMENTAL): During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
- Lenalidomide + dexamethasone (Type: ACTIVE_COMPARATOR): During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study 3 Learning Verbs and Pronouns

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children with or without a diagnosis of ASD between 24 to 71 months of age~* minimum language and nonverbal cognition age of 24 months~Exclusion Criteria:~* native language is not English~* born premature (\< 36 weeks)~* has uncorrected hearing or vision impairments~* has developmental disorders or medical conditions other than ASD that affect language or cognition (excepting psychiatric conditions often comorbid with ASD such as ADHD)~* has a history of photosensitive epileptic seizures

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 71 Months
- Healthy Volunteers: t

Study Arms:
- Addressed (Type: ACTIVE_COMPARATOR): Children participate in an interaction with an experimenter who uses the word to be learned.
- Overheard (Type: EXPERIMENTAL): Children are present in the room while an experimenter uses the word to be learned in an interaction with another experimenter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Marketing Surveillance for Crohn's Disease Participants Treated With Stelara (Ustekinumab)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants who are administered with Stelara for the first time for the indication of Crohn's disease in accordance with the label~* Participants must sign a participation agreement/informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements~Exclusion Criteria:~- Have contraindication to Stelara in accordance to the label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants with Crohn's Disease (Type: None): Participants that are diagnosed with Crohn's disease will be observed in this study who are being treated with ustekinumab under real world clinical practice. Only data available per clinical practice will be collected within this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* chronic renal anemia;~* longterm hemodialysis for \>=12 weeks before screening;~* baseline Hb between 10 and 13g/dL;~* iv or sc maintenance epoetin alfa or beta or darbepoetin alfa therapy with same dosing interval for \>=4 weeks before screening.~Exclusion Criteria:~* acute or chronic bleeding within 8 weeks prior to screening;~* transfusion of red blood cells within 8 weeks prior to screening;~* poorly controlled hypertension necessitating interruption of erythropoetin treatment in previous 6 months;~* previous treatment with Mircera.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gastroesophageal Reflux Disease (GERD) Before and After Gastric Bypass

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Morbid obesity~* Acceptance to undergo open gastric bypass~Exclusion Criteria:~* Prior gastroesophageal surgery~* Achalasia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Patients assessed for GERD (Type: None): Patients who had an open gastric bypass were assessed for GERD before and after surgery following the Montreal Consensus through a validated questionnaire in Portuguese language

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis C virus (HCV) infection~* Non-cirrhotic subjects~* Screening laboratory results showing HCV Genotype 1a (HCV GT1a) infection~* HCV treatment-naïve or if treated previously, only with interferon (IFN) or pegylated interferon (pegINF) with or without ribavirin (RBV)~Exclusion Criteria:~* Pregnant or breastfeeding women~* Positive for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab)~* HCV genotype of any subtype other than GT1a or unable to subtype~* Prior or current use of any investigational or commercially available anti-HCV agents other than IFN, pegIFN or RBV. Subjects with previous participation in trials of investigational direct-acting antiviral agents (DAAs) may be enrolled if they can produce documentation that they received only placebo.~* Current enrollment in another interventional clinical study or receipt of any investigational product within 6 weeks prior to study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3-DAA + RBV 600 mg (Type: EXPERIMENTAL): 3-DAA (ombitasvir/paritaprevir/ritonavir \[25 mg/150 mg/100 mg once daily\] and dasabuvir \[250 mg twice daily\]) plus RBV (ribavirin \[600 mg once daily\]) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age at least 18 years at the time of signing informed consent For Japan only: Male or female, age at least 20 years at the time of signing informed consent~* Diagnosed with T2DM (type 2 diabetes mellitus) for at least 90 days prior to day of screening~* HbA1c (glycosylated haemoglobin) 7.0-10.5 % (53-91 mmol/mol) (both inclusive).~* Stable daily dose of metformin (equal or above 1500 mg or maximum tolerated dose as documented in subject medical record) alone or in combination with SU (= half of the maximum approved dose according to local label or maximum tolerated dose as documented in subject medical record) within 90 days prior to the day of screening~Exclusion Criteria:~* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local regulation or practice). For certain specific countries: Additional specific requirements apply~* Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary Thyroid Carcinoma (MTC)~* History of pancreatitis (acute or chronic)~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)~* Any of the following: myocardial infarction, stroke or hospitalization for unstable angina and/or transient ischaemic attack within the past 180 days prior to the day of screening~* Subjects presently classified as being in New York Heart Association (NYHA) Class IV.~* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.~* Renal impairment defined as estimated Glomerular Filtration Rate (eGFR) below 60 mL/min/1.73 m\^2 as per Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)~* History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and in-situ carcinomas)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 3 mg (Type: EXPERIMENTAL): None
- Semaglutide 7 mg (Type: EXPERIMENTAL): None
- Semaglutide 14 mg (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female from 2 to \<15 years of age.~* Require treatment for the prevention of systemic fungal infection.~* Expected to develop neutropenia (ANC \<500 cells/uL) lasting more than 10 days following chemotherapy.~* Anticipated to live for more than 3 months.~Exclusion Criteria:~* Evidence of any clinically significant liver or renal function or other abnormalities such as cardiac arrhythmia, hypokalemia, hypomagnesemia or hypocalcemia.~* Documented bacterial or viral infection not responding to appropriate treatment.~* Hypersensitivity to or severe intolerance of azole antifungal agents.~* Receiving other azoles or drugs that is are prohibited in the voriconazole label or associated.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1.0 (Type: EXPERIMENTAL): Immunocompromised children aged 2 to \<15 and 12 to \<15 years weighing \<50 kg who are at high risk for systemic fungal infection.
- 2.0 (Type: EXPERIMENTAL): Immunocompromised children aged 12 to \<15 years weighing more than 50 kg who are at high risk for systemic fungal infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a primary DSM-5 diagnosis of Social anxiety disorder (SAD) except those with performance only as a specifier. Participants with a diagnosis of comorbid Generalized Anxiety Disorder (GAD) or Major Depressive Disorder (MDD) may be included if the Investigator considers SAD to be the predominant diagnosis. Participants with current or lifetime history of Attention deficit hyperactivity disorder (ADHD) and specific phobia may be included as well~* Must have a Liebowitz Social Anxiety Scale score greater than or equal (\>=) 70 at Screening and Baseline~* Participants with a current episode of MDD must have a HDRS17 total score less than or equal to (\<=) 18~* Must have a body mass index (BMI) between 18 and 35 kilogram per meter square (kg/m\^2), inclusive, at screening~* Female participants must be either postmenopausal or surgically sterile~Exclusion Criteria:~* Participants who have performance only SAD are excluded. Participants with other current significant psychiatric condition(s) (Axis 1 under DSM-IV), including, but not limited to, MDD with psychotic features (lifetime), bipolar disorder (including lifetime diagnosis), obsessive-compulsive disorder, borderline personality disorder, eating disorder (e.g., bulimia, anorexia nervosa), autism spectrum disorders, post-traumatic stress disorder (PTSD) or schizophrenia are excluded. Participants with a diagnosis of comorbid GAD or MDD may be included~* Participants is currently receiving specific psychotherapy for SAD~* Has a history of more than two unsuccessful adequate pharmacological treatment trials for SAD, defined as lack of response to at least 10 weeks of treatment at adequate doses (e.g., paroxetine \>= 40 milligram per day (mg/day) or its equivalent; or clonazepam \>= 2.5 mg/day or its equivalent)~* Concurrent use of psychotropic medications~* has a history of or current thyroid disease, thyroid dysfunction and is currently untreated for it

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- JNJ-42165279 (Type: EXPERIMENTAL): Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete